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Abstract
Systemic sclerosis is the autoimmune connective tissue disease with the highest morbid-
ity and mortality, through the combination of inflammation, vasculopathy and fibrosis 
leading to severe internal organ involvement. Currently, there are no approved disease-
modifying therapies, and treatment is based on organ-specific treatment and broad immu-
nosuppression, with disappointing long-term results in most cases. Recent research has 
helped to improve knowledge of the pathogenesis of systemic sclerosis and to optimize 
treatment based on specific physiopathological targets, and a new era of biological agents 
in systemic sclerosis has now begun. Promising results are emerging from targeting spe-
cific cytokine signalling, especially IL-6, and cellular subpopulations such as B cells, with 
anti-CD20 therapy, and T-cells, with inhibition of T-cell co-stimulation. Other approaches 
under evaluation are based on the modulation of profibrotic pathways by anti-TGF-β 
agents. In this chapter, we discuss the available evidence to support the use of each biologi-
cal agent in systemic sclerosis based on data from basic and translational research and on 
results from clinical studies.
Keywords: systemic sclerosis, biological therapy, cytokines, immune dysfunction, targeted 
treatment
1. Introduction
Systemic sclerosis (SSc) is a rare multisystem connective tissue disease in which inflamma-
tion, fibrosis, vasculopathy and autoimmunity are the principal features leading to diverse 
organ-based injuries [1]. The complex physiopathology, the substantial clinical heterogeneity, 
the unknown determinants of organ involvement and severity and the different individual 
outcomes that are frequently independent of therapeutic interventions make SSc one of the 
most challenging autoimmune diseases to treat [2–4].
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
With increasing understanding of the mechanisms and the targets underlying the immune 
dysregulation in many autoimmune connective tissue diseases, substantial therapeutic 
advances have been achieved in the past few years, including the development of biological 
therapies [5]. Biological agents have indeed significantly changed the prognosis of different 
conditions not only in rheumatology [rheumatoid arthritis (RA), seronegative spondyloar-
thropathies and systemic lupus erythematous (SLE)] but also in neurological, dermatological 
and gastrointestinal diseases [6–8].
The available treatment approved for SSc is still directed towards organ-associated manifesta-
tions, with cyclophosphamide and mycophenolate mofetil being the main therapeutic options. 
While these treatments may reduce the progression of organ damage, especially cardiac and 
lung disease, their effects are often not sustained [3, 4]. Therefore, the use of targeted therapy 
such as biological agents, acting on the central pathways of the disease, could be considered as 
a true disease-modify treatment for SSc, halting fibrosis and preventing disease progression [5].
In this chapter, we provide an update of the biological agents available for clinical treatment 
of SSc. First, we briefly review the pathogenic pathways that help clarify the targets for such 
therapeutic agents, followed by an overview of the available evidence for the use of each 
biological agent in SSc.
2. Main physiopathological mechanisms with specific treatment  
potential in systemic sclerosis
Vasculopathy, inflammation, autoimmunity and fibrosis are the basis of SSc pathophysiology. 
However, the relative contribution of each of these processes varies, leading to protean manifes-
tations and clinical phenotypes. Hence, the use of specific targeted therapies in SSc is complicated 
by the heterogeneous nature of the disease across patients [2, 3]. Recently, a more integrated 
model based on the interplay between all these processes has been suggested, with sequential 
immune activation and vasculopathy leading to fibrosis, although the primary triggering event 
is still unknown (Figure 1) [4, 9].
Immune activation is thought to be an early event, with circulating and tissue activated CD4+ 
T-cells, production of T helper 2 (Th2) cell-derived cytokines (interleukins 4, 10 and 13) and 
subsequent skin infiltration by macrophages. Differentiation of T helper 17 (Th17) lympho-
cytes may also be an important process in SSc, promoting fibrosis [9, 10]. Gourh et al. ana-
lysed the levels of 13 cytokines in 444 SSc patients and compared with 216 healthy donors. 
They found that SSc patients had higher plasma levels of tumour necrosis factor-α (TNF-α) 
(p < 0.0001) and interleukin-6 (IL-6) (p < 0.001), and lower levels of interleukin-23 (IL-23) 
(p = 0.014). Additionally, cytokine profiles differed in SSc patients based on the presence of 
specific autoantibodies, with IL-6 being elevated in patients with positive anti-topoisomerase I 
and anti-RNA polymerase antibodies, but not in anti-centromere-positive patients. Moreover, 
disease duration also influenced cytokines levels: IL-6 and TNF-α were significantly elevated 
in SSc patients with disease duration between 0 and 10 years, with no difference compared with 
healthy controls for disease duration of more than 10 years. In contrast, levels of interleukin-10 
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(IL-10), interleukin-5 (IL-5) and interferon-γ (IFN-γ) were significantly increased in later 
stages of the disease (>10 years), compared with healthy controls [10].
Although immune activation is more common in the early disease phases, it persists in later 
stages, with B-cells promoting not only the production of antibodies but also interfering with 
antigen presentation, T-cell response and cytokine secretion, mostly through the secretion of IL-6 
and transforming growth factor (TGF-β). In the tight skin mouse (tsk) model of SSc, B-cell deple-
tion leads to suppression of skin fibrosis and downregulation of Th2 cytokines, suggesting a key 
role of B-cells in SSc pathogenesis and providing a link between autoimmunity and fibrosis [11].
Vascular dysfunction and remodelling can also occur early in SSc, resulting from disrupted and 
inappropriate repair processes following endothelial injury, with upregulation of angiogenic 
factors including platelet-derived growth factor (PDGF), vascular endothelial growth factor 
(VEGF), endothelin-1 (ET-1), TGF-β and chemokine ligand 2/chemoattractant protein 1 (CCL2/
MCP-1) [9]. These processes lead to a reduction in the number of capillaries and a narrowing 
of the vessels, impairing blood flow and resulting in tissue hypoxia. The abnormal vascular 
repair may initiate uncontrolled and persistent tissue remodelling, culminating in fibrosis [12].
Among all the cytokines found to be up-regulated in SSc, especially in the skin and lung, 
TGF-β is a potent stimulator of extracellular matrix production and has been widely studied 
and reviewed [13]. It plays an important role in wound healing and tissue repair, and an aber-
rant regulation of TBG-β is associated with inherited conditions, such as hereditary haem-
orrhagic telangiectasia, familial pulmonary hypertension and Marfan syndrome, and with 
fibrotic diseases, such as liver cirrhosis and idiopathic pulmonary fibrosis. In SSc, TBG-β plays 
a major role in fibroblast activation and differentiation and contributes to altered extracellular 
matrix deposition, creating a persistent state of activation. Additionally, TGF-β influences 
Figure 1. Integrated pathogenesis and target molecules in systemic sclerosis. Abbreviations: CCL2, chemokine ligand 
2; CTGF, connective tissue growth factor; ECM, extracellular matrix; ET-1, endothelin-1; IL-1, interleukin-1; IL-4, 
interleukin-4; IL-6, interleukin-6; IL-13, interleukin-13; IL-17, interleukin-17; PDGF, platelet-derived growth factor; TGF-
β, transforming growth factor β and TNF-α, tumour necrosis factor α.
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endothelial cells and the production of anti- and pro-angiogenic factors (increasing VEGF 
and ET-1 expression and downregulating inducible nitric oxide synthase), hence contributing 
to the complex vascular phenotype seen in SSc patients, with proliferative and obliterative 
vascular lesions occurring simultaneously [12, 13].
Many of these molecules are potential targets for biological therapy in SSc. Indeed, many 
of these cytokines are known to correlate with specific organ-based complications in SSc. In 
the study by Gourh et al. described previously, higher serum levels of IL-6 were associated 
with interstitial lung disease (ILD) and pulmonary hypertension (PH), whereas patients with 
increased serum levels of TNF-α were more likely to have SSc renal crisis. IL-6 was also asso-
ciated with higher total skin scores and IL-17 with arthritis [10].
The main effects of the biological agents are (Table 1) [7, 8]:
1. Neutralization of pro-inflammatory cytokines
2. Blockage of co-stimulation between antigen-presenting cells and T-cells
3. B-cell depletion
Most of these biological agents are already approved for the treatment of many autoimmune 
diseases, and for some of them, there are on-going clinical trials in SSc, based on pre-clinical 
work showing the relevance of each of their respective targets in the pathogenesis of SSc.
In the following section, we will review the available evidence to support the use of each bio-
logical agent in SSc, based on data from basic and translational research and on results from 
clinical studies. At the end of this chapter, Tables 2 and 3 summarize the reported experience 
from observational studies and clinical trials for each biological agent in SSc.
Biological agent Biological target
Infliximab, etanercept, adalimumab, golimumab TNF-α
Tocilizumab IL-6
Rilonacept IL-1
Ixekizumab IL-17
Brodalumab IL-17 receptor
Tralokinumab IL-13
Fresolimumab TGF-β
Abatacept CTLA-4 (T-cell)
Rituximab CD20 (B-cell)
Belimumab BAAF (B-cell)
Abbreviations: BAAF, B-cell activating factor; CTLA-4, cytotoxic T-lymphocyte-associated protein-4; IL-1, interleukin-1; 
IL-6, interleukin-6; IL-13, interleukin-13; IL-17, interleukin-17; TGF-β, transforming growth factor β and TNF-α, tumour 
necrosis factor α.
Table 1. Potential targets for current biological therapies in SSc.
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Biological 
agent
First author, 
Year [Ref]
Study 
type
Patients, n Organ 
involvement
Treatment, dose 
and duration
Outcome
Tocilizumab Shima, 2010 
[18]
CS 2 dcSSc 
(patients A 
and B)
ILD (A)
SRC (B)
8 mg/Kg/
monthly
Duration: 6 
months
mRSS reduction:
27→13 (A); 26→20 (B)
Internal organ stable (A,B)
Elhai, 2013
[19]
CHS 15 SSc Polyarthritis 
(n = 15)
8 mg/Kg/
monthly
Duration: 5 
months
DAS-28 score improvement 
(n = 10):
5.2→2.8
Stopped due to inefficacy 
(n = 2)
Fernandes das 
Neves, 2015 
[20]
CS 2 dcSSc 
(patients A 
and B)
1 lcSSc 
(patient C)
ILD (A,B,C) 8 mg/Kg/
monthly
Duration: 6 
months
mRSS reduction:
17→11(A); 41→25(B); 
7→5(C)
ILD: stable (A,B); 
progression (C)
Patient VAS score 
reduction:
70→40(A); 70→30(B); 
60→10(C)
Anti-TNF-α Distler, 2011 
[25]
CS 65 SSc ILD*
Polyarthritis*
Myositis*
INF (n = 30)
ETA (n = 29)
ADA (n = 6)
Duration: not 
specified
Organ involvement:
improvement (n = 48)
- stable (n = 10)
- worsened (n = 7) – mainly 
ILD
Allanore, 2006 
[27]
CR 1 lcSSc ILD and
polyarthritis
ADA
(40 mg sc/every 
2 weeks)
Duration: 7 
months
DAS-28 score 
improvement:
7.8→5.1
ILD progression
Dead from respiratory 
failure
Abatacept Elhai, 2013 
[19]
CHS 12 SSc Polyarthritis 
(n = 12)
Myositis (n 
= 7)
10 mg/Kg/
monthly
Duration: 
variable 11–18 
months
DAS-28 score improvement 
(n = 12)
Median score: 5.2→2.8
Myopathy stable (n = 7)
Paoli, 2014 
[49]
CS 4 dcSSc
(patients A, 
B, C and D)
Extensive 
skin fibrosis 
(A, B, C, D)
ILD (A,B)
500–750 mg/
dose at weeks 
0,2 and 4, then 
every 4 week
Duration: 
variable 12–15 
months
mRSS reduction:
37→8 (A); 32→20 (B); 
35→17 (C); 30→15 (D)
ILD regression (B)
Rituximab Daoussis, 
2012 [63]
CHS 8 dcSSc ILD (n = 8) 375 mg/m2
at baseline, and 
at 6, 12 and 18 
months
At 24 months:
ILD improvement (n = 8)
mRSS reduction (mean 
score):
13.5 ± 12.42→4.87 ± 0.83
Abbreviations: CS, case series; CHS, cohort study; CR, case report; dcSSc, diffuse cutaneous systemic sclerosis; lcSSc, 
limited cutaneous systemic sclerosis; ILD, interstitial lung disease, mRSS, modified Rodnan skin score; SRC, scleroderma 
renal crisis; TCZ, tocilizumab, RTX, rituximab; ADA, adalimumab; ETA, Etanercept; INF, infliximab; VAS, visual 
analogue scale and DAS-28, Disease Activity Score for 28 joints.
*Number of patients not specified.
Table 2. Observational studies and case series reporting the experience of biological therapy in SSc.
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Biological agent First author, year 
[Ref]
Study type Patients, 
n
Control 
Y/N (n)
Treatment Study 
duration
Aim/primary 
end-point
Outcome
Tocilizumab Khanna, 2016 
[21]
RCT 87 
dcSSc
Y (n = 
44)
162 mg sc 
weekly
48 weeks 
(followed 
by open-
label 
weekly 
TCZ for 
48 weeks)
Change in mRSS at 
week 24
Reduction in mRSS at w24:
TCZ −3.92 vs placebo −1.22, (−2.70, p = 
0.0915)
Fewer patients on TCZ with FVC decline vs 
placebo (w24, p = 0.009, w48 p = 0.03)
Infliximab Denton, 2009 [24] OL 16 
dcSSc
N 5 mg/Kg 
at week 
0, 2,6, 14 
and 22
26 weeks Safety assessment 
and potential 
efficacy
No change in mRSS
Frequent AEs (19 treatment-related)
Metelimumab 
(CAT-129)
Denton, 2007 [46] RCT 45 
dcSSc
Y (n = 
11)
0.5, 5 or 10 
mg/Kg
every 6 
weeks
24 weeks Safety assessment No change in mRSS
AEs more frequent in treatment group
Fresolimumab Rice, 2015 [47] OL 15 
dcSSc
N 2 × 1 mg/
kg (4 
weeks 
apart), or 1 
× 5 mg/Kg
24 weeks Safety assessment
Effect on TGF-β 
responsive skin 
gene expression
Downregulation of all TGF-β skin gene 
expression
Reduction in mRSS:
w11 (−6, p = 0.0005); w17 (−9, p = 0.0024)
Frequent bleeding events (n = 11)
Abatacept Chakravarty, 
2011 [50]
RCT 10 
dcSSc
Y (n = 3) 500–750 
mg/dose at 
week 0, 2 
and 4, then 
every 4 
weeks
24 weeks Safety assessment 
and change in 
mRSS at week 24
Reduction in mRSS vs placebo:
−8.6 vs −2.3, p = 0.059
No serious AEs
Chakravarty, 
2015 [51]
RCT 10 
dcSSc
Y (n = 3) 500–750 
mg/dose at 
week 0, 2 
and 4, then 
every 4 
weeks
24 weeks Safety assessment 
and potential 
efficacy
Effect on skin gene 
expression
Reduction in mRSS vs placebo: −9.8,  
p = 0.0014
Decreased inflammatory-related intrinsic 
skin gene expression
Systemic Sclerosis
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Biological agent First author, year 
[Ref]
Study type Patients, 
n
Control 
Y/N (n)
Treatment Study 
duration
Aim/primary 
end-point
Outcome
Rituximab Bosello, 2010 [59] OL 9 dcSSc N 1000 mg day 
1 and 15 
(with 100 mg 
MPDN each)
36 months Safety assessment and 
change in mRSS and 
serum IL-6 levels
At 6 months:
Reduction in mRSS: 21.1 ± 9.0 to 12.0 ± 6.1, p = 0.001
Decrease in serum IL-6 (p = 0.02)
No significant change in FVC or DLCO
Smith, 2010 [60] OL 8 dcSSc N 1000 mg day 
1 and 15 
(with 100 mg 
MPDN each)
24 weeks Safety and potential 
efficacy assessment
At w24
Reduction in mRSS:
24.8 ± 3.4–14.3 ± 3.5, p < 0.001
No significant change in FVC or DLCO
Decrease in myofibroblast score on skin biopsy
Lafyatis, 2009 [61] OL 15 dcSSc N 1000 mg day 
1 and 15
12 months Safety and potential 
efficacy assessment
Change in mRSS
No significant change in mRSS or in FVC or DLCO 
at 6 months
Jordan, 2015 [62] MCNCC 35 dcSSc
11 lcSSc
Y (n = 25) Variable most 
received 1000 
mg at day 1 
and 15
Variable: 7 
months (5–9)
Change in mRSS At 7 months:
RTX group vs baseline: Reduction in mRSS
14.4 ± 1.5 vs 18.1 ± 1.6 v p = 0.0002
no decline in FVC (p = 0.5), improvement in DLCO 
(p = 0.03)
Control group: decline in FVC (p = 0.01)
Daoussis, 2010 [64] RCT 8 dcSSc Y (n = 6) 375 mg/m2 
weekly 4 
weeks, at 0 
and 24 weeks
48 weeks Efficacy assessment At 48 weeks
RTX group vs baseline: Reduction in mRSS
8.37 ± 6.45 vs 13.5 ± 6.84, p < 0.001
Improvement in FVC (p = 0.0018) and DLCO  
(p = 0.017)
Melissaropoulos, 
2015 [65]
OL 30 dcSSc N At 0, 6, 12 and 
18 months*
7 years Long term efficacy and 
safety assessment
Treatment vs baseline:
Lung function improvement
FVC: 86.2 ± 5.5 vs 78.2 ± 3.6, p = 0.018; DLCO:  
62.4 ± 4.5 vs 57.3 ± 3.2, p = 0.012
Reduction in mRSS, (p < 0.001)
5 deaths not proven to be treatment-related
Abbreviations: RCT, randomized controlled trial; OL, open label; MCNCC, multicentre nested case-control; Y, yes; N, no; sc, subcutaneous; FVC, forced vital capacity; 
DLCO, diffusing capacity for carbon monoxide; TCZ, tocilizumab; INF, infliximab; RTX, rituximab; AEs, adverse events; IL-6, interleukin-6 and MPDN, methylprednisolone.
*Dose not specified.
Table 3. Clinical trials investigating the efficacy of biological therapy in SSc.
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3. Targeting pathogenic processes in systemic sclerosis
3.1. Targeting cytokines
3.1.1. Interleukin-6
Multiple lines of evidence indicate that IL-6 is a critical interleukin in SSc. Animal models 
have confirmed this hypothesis. Saito et al. demonstrated that in the bleomycin mouse model, 
the IL-6 knockout (KO) variety had reduced fibrotic bleomycin-induced lung fibrosis, and a 
significant decrease in the total inflammatory cell count, namely macrophages and neutro-
phils, in bronchoalveolar lavage fluid, compared with the wild type (WT) mice (p < 0.05). 
Moreover, lung tissue pathology, on day 21 after bleomycin treatment, showed significant 
fibrotic changes with increased collagen content in WT mice compared with IL-6 KO mice 
(p < 0.05) [14]. Kitaba et al. obtained similar results with IL-6 KO bleomycin mice having 
reduced dermal fibrosis comparing with the WT mice [15].
In a recent work by Khan et al., serum IL-6 levels were determined in 39 patients with diffuse 
cutaneous SSc (dcSSc), 29 patients with limited cutaneous SSc (lcSSc) and 15 healthy controls. 
Serum IL-6 levels were higher in dcSSc patients, especially in the subgroup with thrombo-
cytosis and elevated C-reactive protein levels, compared with dcSSc with normal platelets 
count, lcSSc and controls (p < 0.001). IL-6 expression was higher in dermal fibroblasts and 
endothelial cells especially in patients with early dcSSc (<3 years since disease onset) [16].
The relationship between serum IL-6 levels and clinical outcomes was also addressed. Serum 
IL-6 levels positively correlated with modified Rodnan skin score (mRSS) at the time of dis-
ease onset (Spearman’s p = 0.514, p = 0.001). In addition, serum IL-6 levels at presentation also 
correlated with the mRSS at 36-month follow-up (Spearman’s p = 0.795, p < 0.001), which may 
reflect a predictive role for IL-6 levels regarding the extent of skin involvement in early dif-
fuse patients. Furthermore, these authors also showed that higher levels of IL-6 (≥10 pg/mL) 
at disease presentation predicted mortality in dcSSc, with a 15-year survival of 30% in patients 
with high IL-6 levels vs 93% survival among patients with low IL-6 serum levels (p = 0.021). 
These results reinforce and define a subset of SSc patients in which IL-6 plays a relevant role 
and support the rationale for specific anti-IL6 therapeutics in SSc [16].
Tocilizumab is a humanized anti-IL6 receptor antibody that binds to both the soluble and 
the membrane bound IL-6 receptor, and is approved for the treatment of rheumatoid arthri-
tis amongst other immune-mediated diseases [17]. The first report of SSc patients treated 
with tocilizumab was published in 2010, demonstrating its benefits in two dcSSc patients, one 
with lung fibrosis and the other with renal crisis. Monthly treatment with tocilizumab for 6 
months reduced skin sclerosis in both patients, with skin biopsies showing a reduced number 
of cells in the dermis and vascular walls, and reduced the immunohistochemical staining for 
α-smooth muscle actin (SMA) after treatment. Internal organ involvement remained stable, 
namely lung and renal impairment [18]. Other cases were subsequently reported, reinforcing 
the role of tocilizumab as a valuable treatment option in dcSSc, improving skin thickness, 
halting lung fibrosis and reducing the patient’s Global Disease Activity scores [19, 20].
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In a European League Against Rheumatism (EULAR) Systemic Sclerosis Trials and Research 
Group (EUSTAR) observational study, 15 SSc patients with refractory polyarthritis and 
myopathy were treated with tocilizumab for 5 months, with significant improvement in the 
28-joint count Disease Activity Score in 10 patients. No significant change was seen in lung or 
skin involvement [19].
Another mini-series evaluated the effect of tocilizumab in three dcSSc patients with interstitial 
lung disease. After treatment for 6 months, the skin score improved in all three patients, and 
the patients’ global assessment also improved. In two patients, there was a halt in the progres-
sion of lung fibrosis, on lung high-resolution CT scan (HRCT) and lung function tests [20].
The first clinical trial assessing the effects of subcutaneous tocilizumab in dcSSc (faSScinate) was 
done in 35 hospitals in five different countries (Canada, France, Germany, United Kingdom and 
United States of America) and was published in 2015. In this phase II study, 87 patients with 
early dcSSc (disease duration ≤5 years) were enrolled, 43 patients were treated with tocilizumab 
and 44 with placebo for 48 weeks. The change in the mRSS at 24 weeks was −3.92 in the tocili-
zumab group and −1.22 in the placebo group (difference of −2.70, 95% CI −5.85 to 0.45, p = 0.0915). 
Also, fewer patients assigned for tocilizumab treatment had an absolute decline of forced vital 
capacity (FVC) of more than 10%, compared with patients treated with placebo [21]. Given these 
encouraging results, there is an on-going 2-year randomized double-blinded controlled clinical 
trial, across 120 global study sites, which will assess the efficacy and safety of subcutaneous tocili-
zumab in early dcSSc. The primary outcome measure is the change in mRSS at 48 weeks [22].
3.1.2. Tumour necrosis factor α
Tumour necrosis factor α (TNF-α) is a pro-inflammatory cytokine that plays an important 
role in the pathogenesis of many autoimmune diseases. Anti-TNF-α agents are approved for 
the treatment of rheumatoid arthritis, seronegative spondyloarthropathies and inflammatory 
bowel diseases [7]. Contrasting with its well-proven role in other inflammatory diseases, the 
relevance in SSc and in profibrotic conditions is still conflicting.
Some animal models have shown a benefit from TNF-α blockade. In a study using the bleomycin 
mouse model, treatment with etanercept resulted in a significant reduction in dermal sclerosis 
compared with bleomycin mice not treated with etanercept (dermal thickness 85.83 ± 12.8 vs 
126.4 ± 31.3 μm, respectively, p < 0.05). Histopathological analysis of the skin revealed a reduction 
in the collagen content and in infiltrating myofibroblasts (reduced levels of tissue hydroxypro-
line and α-SMA, p < 0.05) and reduced levels of TGF-β (514.4 ± 62,6 vs 716.9 ± 49.1, treated mice 
vs non-treated, p < 0.05) [23].
The efficacy of anti-TNF-α agents was also assessed in SSc patients. In an open-label study, 16 
patients with dcSSc were treated with infliximab 5 mg/kg (five infusions at weeks 0, 2, 6, 14 
and 22). There was no significant improvement in the mRSS, but there was a trend towards a 
decline between the peak score at 6 weeks (OR 29, 95% CI 11–44) and the 22-week time point 
(OR 17, 95% CI 6–46, p = 0.10). A limiting factor was the frequency of adverse events (total of 
127, with 21 considered serious events and 19 definitively related to infliximab treatment). 
Eight patients (50%) discontinued infliximab prematurely [24].
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In addition, a EUSTAR consensus meeting on the role of anti-TNF-α therapy in SSc con-
cluded that its use in SSc should be discouraged, although it can be considered for patients 
with inflammatory arthritis overlap. These conclusions were based on a review of data on 
anti-TNF-α therapy from 79 EUSTAR centres. From a total of 65 patients treated with TNF-α 
inhibitors, 48 patients (74%) improved, but their main clinical manifestation was inflamma-
tory arthritis. In seven patients (11%), the disease worsened mostly due to progression of lung 
fibrosis, and in two patients (15%), there was no change in the outcome [25].
Furthermore, there is evidence in the literature of progression of lung fibrosis in patients with 
rheumatoid arthritis, mainly related to lung alveolitis after treatment with TNF-α antagonists 
[26], and in the last few years, some similar cases in SSc have been reported. Recently, Allanore 
et al. reported a case of a patient with a 5-year diagnosis of lcSSc with established interstitial lung 
disease with relatively well-preserved lung function (FVC of 72% predicted and diffusing capac-
ity for carbon monoxide (DLCO) of 52%), treated with azathioprine and with progressively dis-
abling inflammatory polyarthritis. Treatment with adalimumab was started with improvement 
in the articular symptoms, but worsening of the lung disease after 6 months of treatment, requir-
ing long-term oxygen therapy and resulting in death from respiratory failure [27].
Due to these reports, anti-TNF-α therapy is now seldom used in SSc patients, based on recom-
mendations by experts and despite the absence of randomized controlled trials.
3.1.3. Interleukin-1
The role of interleukin-1 (IL-1) in the pathogenesis of SSc has been addressed in a few studies. 
The IL-1 role in proliferation and collagen production of fibroblasts is well established. After 
IL-1 stimulation, normal fibroblasts produce various cytokines, including IL-6, IL-8, TNF-α 
and PDGF. IL-1α is elevated in the serum of SSc patients, and it is constitutively produced 
by SSc fibroblasts, as demonstrated by Maekawa et al. [28]. In this study, IL-1α levels were 
significantly higher in SSc patients compared with healthy controls (p = 0.0017), although the 
stratification of SSc patients according to disease subsets (limited vs diffuse) did not show a 
significant difference in serum IL-1α levels. Furthermore, Kawaguchi et al. demonstrated that 
inhibition of IL-1α in SSc fibroblasts resulted in decreased fibroblast proliferation, decreased 
IL-6 production and procollagen synthesis, whilst overexpression of IL-1α in normal fibro-
blasts resulted in an SSc phenotype fibroblast [29].
Considering these results, a phase I/II double-blinded placebo-controlled trial is on-going 
in patients with early dcSSc in order to assess the effects of rilonacept (IL-1 Trap), an anti-
IL-1 antibody, currently used for autoinflammatory syndromes such as cryopyrin-associated 
periodic syndromes. In this study, the primary outcome is the 4-gene biomarker expression 
in the skin, and the secondary outcome is the reduction of skin thickness measured by mRSS. 
Farina et al. previously described the 4-gene biomarker as highly predictive of mRSS in 
patients with early dcSSc. It includes two TFG-β-regulated genes: cartilage oligomeric matrix 
protein (COMP) and thrombospondin-1 (THS1), and two interferon (IFN)-regulated genes: 
interferon-induced 44 (IFI44) and sialoadhesin (SIG1). The central hypothesis is that if IL-1 is 
a key cytokine leading to fibrosis in SSc, its inhibition will downregulate the expression of the 
4-gene biomarker in the skin [30, 31].
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3.1.4. Interleukin-13
Substantial experimental evidence has shown that interleukin-13 (IL-13) has a significant role 
in SSc as a profibrotic cytokine that interplays with other mediators such as TGF-β [2, 6, 32].
Fichtner-Feigl et al. have recently defined the pathway of IL-13-induced fibrosis via TGF-β in 
an in vivo bleomycin model of fibrosis. Firstly, this process involves the induction of a cell-sur-
face IL-13 receptor (IL-13Rα
2
) by IL-13 and TNF-α. In a second phase, IL-13 signalling through 
this receptor induces activation of the TGFB1 promoter. Prevention of IL-13Rα
2
 expression via 
IL13Rα
2
 gene silencing or blockade of the IL-13Rα
2
 signalling leads to marked downregula-
tion of TGF-β production and collagen deposition in bleomycin-induced lung fibrosis [32].
Fuschiotti et al. analysed the ability of SSc patients’ CD4+ and CD8+ T-cells to produce cyto-
kines following in vitro activation. There was a dysregulation in IL-13 production by effec-
tor CD8+ T-cells in SSc, not present in the healthy control group or in rheumatoid arthritis 
patients (p < 0.001). This dysregulated IL-13 production also correlated with the extent of skin 
fibrosis, with dcSSc showing higher levels of IL-13 compared with lcSSc (p < 0.01) [33].
Supporting this work, Bleperio et al. also concluded that in the bleomycin-induced mouse 
model, IL-13 levels were elevated and its neutralisation led to attenuation of bleomycin-
induced pulmonary fibrosis and to a decrease in C10 levels (a chemotactic factor for mono-
nuclear phagocytes) [34].
Moreover, in another work from Fuschiotti et al., circulating IL-13 producing CD8+ T-cells in 
SSc expressed skin-homing receptors and induced a profibrotic phenotype in normal fibro-
blasts which was inhibited by an anti-IL13 antibody. The histopathological analysis showed 
a dermal inflammatory infiltration of CD8+ T-cells and the IL-13 accumulation was higher in 
the early phases of the disease (duration <3 years) [35].
Tralokinumab is an interleukin-13 neutralising humanized monoclonal antibody used in 
uncontrolled severe asthma. It seems to be particularly effective in the subgroup of patients 
with higher baseline levels of periostin, an IL-13-induced protein in the airways, which is also 
elevated in SSc patients [36]. Yang et al. showed that after bleomycin treatment, WT mice had 
marked cutaneous fibrosis, increased expression of periostin and increased numbers of myo-
fibroblasts, while these changes were not seen in periostin−/− mice (PN−/−). Moreover, fibro-
blasts of PN−/− mice showed reduced expression of α-SMA and procollagen type-Iα1 induced 
by TGF-β. Also, SSc patients had elevated expression of periostin in the skin compared with 
healthy controls [37]. Tralokinumab is currently under evaluation in a phase II dose-ranging 
study for patients with idiopathic pulmonary fibrosis [38].
Altogether, there is significant research supporting a possible role for tralokinumab in SSc 
treatment, especially in patients with interstitial lung disease.
3.1.5. Interleukin-17
Interleukin-17 (IL-17) is a cytokine secreted by a distinct T-cell subset called T helper 17 (TH17) 
cells, which leads to activation of fibroblasts and subsequent secretion of pro-inflammatory 
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cytokines such as IL-6 and IL-8, and to an increased surface expression of Intercellular 
Adhesion Molecule 1 (ICAM-1). In a work by Kurasawa et al., IL-17 was found to be overex-
pressed in peripheral blood cells and in lymphocytes from the skin and lungs of SSc patients, 
compared with samples from patients with systemic lupus erythematosus, autoimmune 
inflammatory myositis and healthy donors. Furthermore, IL-17 overproduction significantly 
correlated with an early disease stage and an enhanced proliferation of fibroblasts and IL-1 
production in SSc patients [39]. Altered IL-17 expression in SSc has also been reported else-
where, with studies documenting a decrease in regulatory T-cell (Treg) levels, as well as a 
functional deficiency, accompanied by an increase in CD4+CD25+FoxP3+ T-cells and IL-17 
levels, potentially causing an immune imbalance between Treg and Th17 cells [40, 41].
Recently, studies have started looking at several biological agents that target IL-17 (ixeki-
zumab) and its receptor (brodalumab), especially in psoriatic arthritis, but currently there are 
no data available on its use in SSc [42].
3.2. Targeting morphogenic regulators
3.2.1. Transforming growth factor-β
Transforming growth factor-β (TGF-β) has been recognised as the central mediator of fibrosis 
in SSc and the persistence of TBG-β signalling is a key feature in SSc pathogenesis [43]. TGF-β 
is secreted from monocytes, lymphocytes and fibroblasts in the latent form and sequestered 
in the extracellular matrix. In its active form, TGF-β promotes collagen gene expression and 
sustained fibrosis via SMAD (mothers against decapentaplegic) 2/3 signalling and epithelial-
mesenchymal transition through a SMAD-independent pathway [44, 45].
Examining the role of TGF-β in fibrosis, Sargent et al. assessed TGF-β responsive gene expres-
sion in the skin of SSc patients. This TGF-β responsive signature was found only in patients 
with the diffuse subset and correlated with higher mRSS and with a higher prevalence of 
interstitial lung disease. There was no association between disease duration, specific autoan-
tibodies or any other clinical manifestation and TGF-β-expression gene signature [43].
The blockade of TGF-β pathways has been shown to prevent collagen synthesis in SSc fibro-
blasts. Ihn et al. evaluated the levels of active and latent TGF-β and its receptor from cultured 
dermal fibroblasts of 10 patients with early dcSSc (<2 years disease duration). They also exam-
ined the expression of human α2(I)-collagen messenger RNA (mRNA) and its transcriptional 
activity both before and after blocking TGF-β signalling with anti-TGF-β antibodies or with a 
TGF-β anti-sense oligonucleotide. SSc fibroblasts produced an equivalent amount of TGF-β as 
control fibroblasts (0.381 ± 0.031 vs 0.435 ± 0.082, respectively), although SSc fibroblasts had a sig-
nificantly increased expression of TGF-β receptors (p < 0.01). Furthermore, the blockage of TGF-β 
signalling resulted in a dose-dependent decrease of α2(I)-collagen mRNA expression [44].
Given the role of TGF-β in SSc pathogenesis and the availability of commercial anti-TGF-β 
antibodies, some recent trials tested their safety and efficacy in the treatment of SSc.
In a multi-centre randomised placebo-controlled trial, 45 early dcSSc patients were treated 
with CAT-192 (Metelimumab), a recombinant human antibody that neutralises active human 
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TGF-β1 (doses of 0.5, 5 or 10 mg/kg, in a total of four administrations, every 6 weeks). The 
primary endpoint was to evaluate safety and tolerability of CAT-192; secondary outcomes 
included mRSS, Systemic Sclerosis Health Assessment Questionnaire, organ-based manifes-
tations, levels of collagen propeptides (N propeptide and type I and type III collagen) and skin 
levels of mRNA for procollagen I and III, TGF-β1 and TGF-β2. No changes in mRSS or in any 
other clinical variables assessed were documented, including the levels of biomarkers in the 
serum and the mRNA analysis of skin biopsies, independently of the dose used. Moreover, 
there were more serious adverse events, including deaths, than in the placebo group (four 
deaths in the treatment group vs zero in the placebo group) [46].
Contrasting with CAT-192 that has a weak neutralising effect and is monospecific for TGF-β1, 
fresolimumab is a high-affinity neutralising antibody that targets all three TGF-β isoforms. 
In an open-label trial, 15 patients with early dcSSc were divided in two groups and treated 
with fresolimumab (either two infusions of 1 mg/kg 4 weeks apart, or one infusion of 5 mg/
kg). The skin expression of TGF-β-regulated genes was assessed, as well as skin thicken-
ing using mRSS. At weeks 3 and 7 after treatment, there was a downregulation of all the 
TGF-β-regulated biomarker genes studied, namely thrombospondin-1 (THBS1), cartilage 
oligomeric protein (COMP), Serpin Family E Member 1 (SERPINE1) and connective tissue 
growth factor (CTGF) in both groups. There was also a parallel improvement in mRSS, with 
a mean change in mRSS in both groups of −6 (p = 0.0005) and −9.5 (p = 0.0024), at weeks 11 
and 17, respectively, compared with baseline. SMA staining on skin biopsies also decreased 
significantly (p < 0.01, comparing week 4 to baseline). Regarding safety, one patient died of 
congestive heart failure 12 weeks after fresolimumab treatment. The most significant adverse 
events were bleeding episodes (11 patients, two of them with gastrointestinal bleeding) and 
anaemia in 10 patients (66.7%) [47]. By considering these results and fresolimumab’s effect as 
an antifibrotic agent, further studies are needed to determine the safety profile of fresolim-
umab and its effects on organ involvement in SSc.
3.3. Targeting of cellular subpopulations
3.3.1. T-cells
As described previously, activated T-cells play an important role in SSc pathogenesis. Abatacept is a 
soluble fusion protein consisting of an extracellular domain of the human cytotoxic T-lymphocyte-
associated antigen 4 (CTLA4), linked to the modified fragment crystallizable (FC) region of IgG1. 
It inhibits T-cell activation by binding CD80/CD86 on antigen presenting cells, blocking its interac-
tion with CD28 on T-cells. It is currently approved for the treatment of rheumatoid arthritis [7].
In mouse models of bleomycin-induced dermal fibrosis and chronic graft-vs-host disease 
(early and inflammatory stages of SSc), abatacept prevented skin fibrosis and it was also 
effective in treating established fibrosis. Activated T-cells, B-cells and monocytes infiltrating 
the skin were reduced, along with IL-6 and IL-10 levels. However, abatacept did not have 
any efficacy reducing dermal fibrosis in Tsk-1 mice (inflammatory-independent mouse model 
of SSc) reinforcing the concept that inhibition of T-cell response by abatacept can only pre-
vent and reduce inflammation-driven dermal fibrosis. Moreover, abatacept did not protect 
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against bleomycin-induced dermal fibrosis in CB17-SCID mice, further supporting the idea 
that T-cells have a role in the anti-fibrotic effect of abatacept [48].
Some case reports and observational studies have shown the benefit of abatacept in SSc 
patients. In a small clinical report of four patients with dcSSc refractory to conventional ther-
apy, abatacept was administered intravenously at weeks 0, 2 and 4, and then every 4 weeks. All 
four patients had severe progression of skin thickness, and two of them had interstitial lung 
disease under conventional therapy (cyclophosphamide and low-dose prednisolone). After 
adding abatacept, a decrease in mRSS was achieved in all patients (average of 1.3 units/month) 
and lung function improved 6 months after starting abatacept. Furthermore, these effects were 
sustained even after tapering the other treatments [49]. In an observational EUSTAR study 
in 20 SSc patients with refractory polyarthritis and myositis, treatment with abatacept for a 
mean of eleven months showed benefits in polyarthritis with a reduction of the 28-joint count 
Disease Activity Score but it showed no efficacy in muscle involvement. There was also no dif-
ference in mRSS, but only half of these patients had dcSSc and the mean baseline mRSS was 
only 5 [19].
In addition, Chakravarty et al. carried out a pilot study in 10 early dcSSc patients (seven 
treated with abatacept at 0, 2, 4 and every 4 weeks, for 24 weeks; three patients treated with 
placebo). Compared to placebo, patients treated with abatacept showed a greater improve-
ment in absolute mRSS (−8.6 vs −2.3, p = 0.059) and a higher mean percentage of change in 
mRSS (−33% vs −6.2%, respectively, p = 0.31). No changes in the other variables were docu-
mented, namely in lung function tests. There were no serious adverse events [50].
Recently, the same group performed a randomised placebo-controlled clinical trial to evalu-
ate the effect of abatacept and to assess safety outcomes in 10 SSc patients (seven treated 
with abatacept for 24 weeks and three with placebo). Improvement in mRSS was defined as 
≥30% from baseline; skin biopsies were obtained for differential gene expression and intrinsic 
gene expression subset assignment (inflammatory signature, fibroproliferative signature and 
normal-like signature). This included biopsies from four healthy controls [51].
There was a trend towards improvement in mRSS in the treatment group at week 24, when 
compared to the baseline (−8.6 ± 7.5, p = 0.0625), but not to the placebo group (−2.3 ± 15, 
p = 0.75). When accounting for repeated measures over the eight visits of the study, there was a sig-
nificant difference between the two groups, with a decrease estimate of −9.8 (95% CI −16.7 ± 3.0, p = 
0.0014) in mRSS. Five of the patients in the treatment group and one in the placebo group showed 
a decrease in mRSS ≥ 30%. Adverse events were similar in both groups, with one serious adverse 
event in the treatment group (supraventricular tachycardia), considered to be unrelated to the 
study drug and the patient completed the study. Patients who improved with abatacept mapped 
to the inflammatory intrinsic subset of skin gene expression at baseline and showed decreased 
gene expression after treatment, mainly in genes related to CD28 T-cell co-stimulation, whereas 
non-improvers and the placebo group showed stable or reverse inflammatory gene expression [51].
Given these data, the same group is currently conducting a larger multi-centre placebo-controlled 
trial for subcutaneous abatacept in early dcSSc. In addition to safety assessment, the primary 
outcome of this trial is variation in mRSS [52].
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3.3.2. B-cells
The findings of pre-clinical and clinical works suggest an important role for B-cells in the 
physiopathology of SSc. SSc patients have an altered blood B-cell homeostasis, with stud-
ies showing expanded naive B-cells, activated but diminished memory B-cells, and chronic 
hyper-reactivity of memory B-cells [53, 54]. Additionally, DNA microarrays of gene expres-
sion patterns in skin biopsies of dcSSc patients have revealed a B-lymphocyte signature when 
compared to healthy controls, and this was present in both affected and unaffected skin [55].
B-cell infiltration was also found in lung biopsies of SSc patients with interstitial lung disease 
(ILD). Lafyatis et al. analysed pulmonary tissue of 11 patients with dcSSc (four with non-specific 
interstitial pneumonia and seven with a usual interstitial pneumonia pattern). Tissue was 
stained for CD20, CD3 and CD68 and compared with lung biopsies from four healthy controls. 
Lung tissue from SSc patients showed a variable but intense infiltration of B-cells arranged 
in lymphoid aggregates as well as in a diffuse pattern. Staining tended to be more intense in 
patients with the usual interstitial pneumonia (UIP) pattern, but the correlation was not statisti-
cally significant, possibly due to the small sample size. These data suggest that B-cells could be 
important in the pathogenesis of ILD in SSc, and considering the variability of B-cell infiltration, 
anti-CD20 therapy can be a therapeutic option at least in a subset of patients with SSc [56].
Contributing to probable relevancy of B-cells in SSc, serum levels of B-cell activating factor 
(BAAF) were also shown to be elevated in SSc patients, correlating with the extent of skin 
fibrosis. BAAF is a member of the tumour necrosis factor (TNF) superfamily and plays an 
important role in the survival and maturation of B-cells. It influences all stages of B-cell differ-
entiation, from development, selection and homeostasis of naive primary B-cells to the mainte-
nance of long-lived bone marrow plasma cells. BAAF excess rescues self-reactive B-cells from 
anergy, contributing to autoimmunity. Matsushita et al. examined BAAF levels in the serum 
of 21 SSc patients (both diffuse and limited subsets) and related the results to clinical features 
of the patients. Serum BAAF levels were significantly higher in patients with SSc when com-
pared with healthy controls [median 1.26 ng/mL (0.32 − 1.37) vs 0.78 ng/mL (0.39.1.37), respec-
tively, p < 0.001], and patients with dcSSc had higher levels than lcSSc (p < 0.05). BAAF levels in 
SSc correlated positively with mRSS (r = 0.415, p < 0.005). A longitudinal study of BAAF levels 
for 6 years classified SSc patients as follows: 7 patients had decreased BAAF levels, 11 had 
unchanged levels and 3 had increased levels. Decreased BAAF levels were associated with a 
significant decrease in mRSS from baseline to 2 years (36%, p < 0.05), 4 years (45%, p < 0.05) 
and 6 years (54%, p < 0.05). In the three patients in whom BAAF levels remained high, there 
was no change in mRSS, and new onset/worsening of internal organ involvement (renal crisis 
and deterioration of ILD) was documented. In the group in whom BAAF levels remained 
unchanged, mRSS tended to decrease, but it was not statistically significant [57].
The levels of BAAF receptor were also higher in SSc compared to controls (mean 81 ± 40 vs 
43 ± 7, p < 0.05). Moreover, BAAF mRNA expression in affected skin from SSc patients was 
significantly upregulated in early SSc patients (disease duration <3 years) compared with 
late SSc patients (>6 years disease duration) and normal controls (p < 0.005 and p < 0.0001, 
respectively). The expression of BAAF mRNA in the skin of late SSC and normal controls 
was not significantly different. To evaluate the role of BAAF in B-cell function of SSc, B-cells 
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were stimulated with BAAF and the amounts of IL-6 and IgG were determined. SSc B-cells 
produced 38% more IL-6 and 35% more IgG than B-cells from healthy controls [57].
B-cell depletion has been proven to be effective in reversing skin fibrosis both in animal mod-
els of SSc and in small case series and clinical trials. Studies in the tsk mouse model showed 
that B-cell depletion by an anti-CD20 antibody inhibited the development of autoimmunity 
and skin fibrosis when initiated early in the course of disease. In a study by Hasegawa et al., 
B-cell depletion using an anti-mouse CD20 monoclonal antibody before (at day 3 after birth) 
and after disease development (day 56) resulted in reduced skin fibrosis, decreased autoanti-
body generation and decreased levels of hypergammaglobulinemia in new born mice, but not 
in adult mice with established disease [58].
Rituximab is a chimeric anti-CD20 monoclonal antibody largely used in rheumatology for the 
treatment of RA, SLE and more recently for Anti-neutrophil cytoplasmic antibody (ANCA)-
positive vasculitis [7]. In an open-label trial, Bosello et al. treated nine dcSSc patients with 
rituximab, and analysed long-term safety, skin score and serum levels of IL-6. After treat-
ment, at 6 months, there was an improvement in mRSS from 21.1 ± 9.0 to 12.0 ± 6.1 (p = 0.001), 
with a median decrease of 43.3% (range from 21.1 to 64.0%), a parallel fall in IL-6 serum levels 
(from 3.7 ± 5.3 to 0.6 ± 0.9 pg/mL, p = 0.02) and an improvement in the Health Assessment 
Questionnaire (HAQ) score (from 0.9 ± 0.7 to 0.4 ± 0.5, p = 0.01). The FVC and DLCO levels 
showed no significant difference at follow-up compared with baseline. Nevertheless, none of 
the patients had a clinically significant reduction in FVC values (>10%). Moreover, none of the 
patients had new or progressive cardiac involvement, renal crisis or symptoms suggesting 
progressive gastrointestinal disease [59].
Smith et al. obtained similar results in a 24-week open-label clinical trial in eight dcSSc 
patients. Rituximab induced effective B-cell depletion in all patients and improved the 
skin score from 24.8 ± 3.4 to 14.3 ± 3.5 (p < 0.001) at 24 weeks. Parameters of internal organ 
involvement remained stable, namely lung function tests. Histopathological study of the skin 
revealed a decrease in the mean hyalinised collagen score from 60 ± 6.5 to 7.1 ± 7.2 (p < 0.0001) 
and abolished myofibroblast positivity [4/7 vs 0/8, (χ2 test p = 0.013)] [60].
In another small pilot study, Lafyatis et al. assessed rituximab safety, clinical efficacy and result-
ing skin B-cell and autoantibody depletion in 15 patients with early dcSSc (less than 18 months 
prior to trial entry). The mRSS did not change significantly between baseline and 6 months. 
Similarly, both predicted FVC and DLCO remained unchanged at 6 months after treatment. 
Nevertheless, none of the patients showed evidence of progression of major organ involve-
ment. Circulating B-cell depletion was achieved in all patients at 3 months, with recovery at 
6–12 months. Also, most patients showed complete depletion of skin B-cells, with an average 
quantification per specimen at baseline of 10.4, compared with 3.4 at 6 months. Autoantibody 
levels declined modestly but the changes were not consistent during follow-up [61].
In a large observational case-control series of 63 SSc patients (both diffuse and limited) from 
the EUSTAR cohort, mRSS decreased significantly from 18.1 ± 1.6 to 14.4 ± 1.5 (p = 0.0002) 
and there was also a significant decrease in the mean percentage of change from baseline of 
−15.0 ± 5.3% (p = 0.008) on follow-up at 7 months. Furthermore, in patients with SSc-related 
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ILD, FVC was stable after treatment, compared with baseline (60 ± 2.4 vs 61.3 ± 4.1%, p = 0.5), 
whereas DLCO significantly improved (41.1 ± 2.8 vs 44.8 ± 2.7%, p = 0.03). In contrast, matched 
controls from the EUSTAR database showed a decline in FVC in both the mean percentage of 
predicted value (p = 0.02) and in absolute change (p = 0.01) [62].
Focusing on lung fibrosis, Daoussis et al. studied eight dcSSc patients with ILD treated with 
rituximab, during a 2-year follow-up [63]. Similarly to previous results from a smaller scale 
study from the same group [64], there was a significant increase from baseline in both FVC 
(mean 68.13 ± 19.69 vs 75 ± 19.73, p = 0.0018) and DLCO (mean 52.25 ± 20.71 vs 62 ± 23.21, 
p = 0.017), reinforcing the benefits of rituximab treatment in SSc-associated ILD. In a larger 
population of 30 patients, the same group performed a 7-year follow-up open-label multi-
centre study, with results supporting the benefits of continuous rituximab treatment for skin 
involvement and SSc-related ILD. Patients were treated at baseline, 6, 12 and 18 months. Both 
FVC and DLCO improved after 2 years (mean FVC: 86.2 ± 5.5 vs 78.2 ± 3.6, p = 0.018; mean 
DLCO: 62.4 ± 4.5 vs 57.3 ± 3.2, p = 0.012, treatment vs baseline, respectively). There was a 
trend towards stabilisation after 2 years of treatment (mean FVC 84.3 ± 6.5 at 5 years, p = 0.04). 
However, in three patients who had an initial improvement or stabilisation of lung function 
with continuous treatment, there was deterioration in the lung function tests after 3 years of 
rituximab cessation and they did not respond to retreatment. Corroborating previous results, 
an early improvement in mRSS was also achieved at all time-points compared with baseline 
(p < 0.001) [65].
Considering the role of B-cells in SSc and positive results associated with its depletion, several 
clinical trials are on-going with rituximab and belimumab, an anti-B-lymphocyte stimulator 
monoclonal antibody used in patients with SLE, but no preliminary results are yet available [66].
In the study Rituximab in Systemic Sclerosis (RECOVER) the primary outcome is the treat-
ment of polyarthritis (through analogy with rheumatoid arthritis), and the secondary out-
comes are improvements in mRSS, lung function tests and quality of life [67].
Another on-going trial aims to validate an infusion protocol-based treatment for early diffuse 
SSc with rituximab, using a dose of 1000 mg intravenously, at day 1 and 15 and then at week 
26–28, together with a corticosteroid regimen consisting of intravenous methylprednisolone 
100 mg, 30 minutes prior to both infusions. Clinical variables will be assessed after 28 weeks, 
namely survival rate, presence of heart and lung failure and antibody titres [68].
Based on pre-clinical data and anecdotal reports, which suggest that modulation of the 
immune system may be an effective strategy for treating pulmonary arterial hypertension 
in SSc, patient recruitment is currently underway for a randomised double-blinded placebo-
controlled trial (phase II) to evaluate the effects of rituximab on this severe manifestation of 
the disease. The primary outcome is the change in pulmonary vascular resistance measured 
by right heart catheterisation, assessed at week 24. Patients will still receive concurrent stable-
dose standard therapy with a prostanoid, endothelin receptor antagonist and/or phospho-
diesterase-5 inhibitor. In a sub-study, cardiac magnetic resonance will be used to evaluate 
changes in right ventricular end diastolic volume index and stroke volume, as measures of 
right ventricular function [69].
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4. Conclusions
The interplay of vasculopathy, fibrosis, inflammation and autoimmunity makes SSc a com-
plex disease. The growing understanding of its pathogenesis has increased the identifica-
tion of potential targets, and thereby the use of specific therapies such as biological agents. 
Although most studies and clinical trials are restricted to a subgroup of SSc patients, mainly 
with the early diffuse cutaneous subset, the results are encouraging for some biologicals, 
especially B-cell depleting agents and anti-IL6 drugs for skin and lung involvement.
While tocilizumab has shown benefits in reducing skin fibrosis and halting progression of 
interstitial lung disease, data on rituximab are more consistent in relation to improvement of 
lung fibrosis, at least in early disease stages, although the benefits in later phases are not clear.
Apart from anti-IL6 antagonists, other biologicals targeting cytokines are not yet valuable options 
for SSc treatment. All three cytokines, IL-17, IL-13 and IL-1, are relevant in fibrosis mechanisms, 
but the clinical utility of their antagonists in SSc is still unknown. Anti-TNF-α therapy can be 
beneficial in a highly selected subgroup of patients with inflammatory arthritis overlap, although 
its use is not recommended for SSc, due to concerns related to worsening interstitial lung disease.
Other therapeutic approaches such as T-cell target therapy (abatacept) have had good results, 
although limited to skin fibrosis and arthritis, and without any proven benefits for SSc organ-
based complications. Additionally, despite the key role of TGF-β in the pathogenesis of SSc, 
clinical use of TGF-β antagonists did not show any benefits regarding internal organ involve-
ment, and there were serious treatment-related adverse events.
Although some of the results from clinical trials in SSc are compelling, primary outcomes 
mostly address only skin fibrosis and lung disease, probably reflecting the lack of validated 
internal organ assessment outcome measures, especially for gastrointestinal and cardiac com-
plications. Nevertheless, randomised clinical trials are necessary to validate new therapies as 
the standard of care in clinical practice. Hence, apart from better insights into disease mecha-
nisms, which will help to identify new therapeutic targets, improvement in clinical trial design, 
with better cohort definition and updating of traditional clinical end-point assessment, will 
provide more robust results to inform the clinical applicability of biological therapies in SSc.
Based on the complexity of SSc pathogenesis and early indicators from the studies up to date, 
it seems likely that future treatment approaches may be built around targeting multiple path-
ways simultaneously. This may means combined therapy using both biologicals and small 
molecule inhibitors, such as tyrosine kinases, although issues related to adverse events and 
cost would have to be addressed.
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